Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
4.480
-0.210 (-4.48%)
At close: Feb 21, 2025, 4:00 PM
4.840
+0.360 (8.04%)
After-hours: Feb 21, 2025, 7:07 PM EST
Traws Pharma Employees
As of December 31, 2023, Traws Pharma had 18 total employees, including 17 full-time and 1 part-time employees. The number of employees increased by 1 or 5.88% compared to the previous year.
Employees
18
Change (1Y)
1
Growth (1Y)
5.88%
Revenue / Employee
$12,556
Profits / Employee
-$7,821,389
Market Cap
16.36M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
TRAW News
- 4 weeks ago - Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu - PRNewsWire
- 6 weeks ago - Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program - PRNewsWire
- 7 weeks ago - Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval - PRNewsWire
- 2 months ago - Traws Pharma stock soars 200% on encouraging bird flu drug data - Invezz
- 2 months ago - Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu - PRNewsWire
- 3 months ago - Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results - GlobeNewsWire
- 4 months ago - Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - GlobeNewsWire
- 5 months ago - Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor - GlobeNewsWire